In Vivo Model Development for Immunodeficiency Disorders
Protheragen is dedicated to advancing immunodeficiency disorder research by providing comprehensive in vivo animal model development services. Our expert team leverages cutting-edge methodologies and a wide range of validated animal models to support the preclinical evaluation of novel therapeutics targeting immunodeficiency conditions. We offer tailored solutions to meet the unique requirements of each research project, ensuring reliable, reproducible, and translational results.
Immunodeficiency disorders encompass a diverse group of conditions characterized by impaired immune system function, leading to increased susceptibility to infections and other complications. Animal models are indispensable tools for unraveling disease mechanisms, evaluating therapeutic efficacy, and understanding immune responses in vivo. At Protheragen, we utilize multiple species, including mice (such as BALB/c, C57BL/6, and NOD-SCID strains), rats, and occasionally larger animals, to closely mimic human immunodeficiency pathophysiology. These models allow for the study of both primary and secondary immunodeficiencies and facilitate the translation of research findings into clinical applications.
Chemically-induced immunodeficiency models are established by administering immunosuppressive agents such as cyclophosphamide, dexamethasone, or busulfan to experimental animals. This approach leads to transient or sustained suppression of immune cell populations, recapitulating acquired immunodeficiency states. Key advantages include rapid induction, dose-dependent effects, and reversibility, making them ideal for short-term studies and drug screening. These models are primarily used for evaluating immunomodulatory agents, studying immune cell recovery, and assessing infection susceptibility.
Genetic models involve the use of animals with targeted mutations or naturally occurring genetic defects that result in immunodeficiency, such as SCID (Severe Combined Immunodeficiency) mice, NOD-SCID, or knockout strains lacking specific immune components (e.g., Rag1/2, IL2rg). These models closely mimic human primary immunodeficiencies, offering high translational relevance and stable phenotypes. They are invaluable for mechanistic studies, cell and gene therapy research, and long-term therapeutic efficacy evaluation.
Dietary-induced immunodeficiency models are created by subjecting animals to specific nutritional deficiencies, such as protein-energy malnutrition or micronutrient deprivation (e.g., zinc, vitamin A). This leads to compromised immune function and increased infection risk, mirroring secondary immunodeficiency seen in malnourished patients. These models are advantageous for studying the interplay between nutrition and immune health, evaluating nutritional interventions, and investigating host-pathogen interactions in immunocompromised states.
Protheragen offers a complete, end-to-end solution for in vivo immunodeficiency disorder model development. Our services include model selection and customization, animal procurement and housing, induction and validation of immunodeficiency, therapeutic administration, and comprehensive data analysis. Key efficacy endpoints measured include immune cell profiling (flow cytometry), cytokine/chemokine quantification (ELISA, multiplex assays), infection challenge studies, survival analysis, histopathology, and functional immune assays. Our analytical capabilities extend to molecular, cellular, and systemic evaluations, ensuring robust data generation. Stringent quality control measures, including SOP-driven protocols, regular health monitoring, and ethical compliance, guarantee the reliability and reproducibility of results.
Partnering with Protheragen means gaining access to a team of experienced scientists, state-of-the-art facilities, and a commitment to scientific excellence. We work closely with our clients to design and execute studies that accelerate the development of immunodeficiency disorder therapeutics. Discover how our in vivo model development services can empower your research—contact Protheragen today to discuss your project needs.
Make Order
Experimental Scheme
Implementation
Conclusion
